| Discovery cohort | Discovery cohort normal | Validation cohort | Validation cohort normal | Tissue |
---|---|---|---|---|---|
Number of patients | 39 | 10 | 98 | 25 | 12 |
Age (mean ± SD) | 58 ± 16 | 60 ± 6 | 55 ± 12 | 57 ± 12 | 59 ± 16 |
Subtype of cancer | 39 IDC | Â | 89 IDC 9 ILC | Â | 12 IDC |
Size of invasive cancer (mm) | 30.5 ± 25.2 |  | 26.4 ± 14.5 |  | 43.1 ± 35.5 |
Lymph node negative (%) | 19 (48.7%) | Â | 40 (44.9%) | Â | 5 (41.7%) |
Number of positive axillary lymph nodes | 3.0 ± 6.4 |  | 2.8 ± 5.4 |  | 5.6 ± 10.2 |
ER positive | 28 (71.8%) | Â | 69 (77.5%) | Â | 8 (66.7%) |
PR positive | 22 (56.4%) | Â | 69 (77.5%) | Â | 6 (50.0%) |
HER2 positive | 6 (15.4%) | Â | 18 (20.2%) | Â | 3 (25.0%) |